Recardio at BIO Europe 2026
San Francisco, October 05, 2026 - Recardio Inc., a late-stage clinical biotechnology company developing therapies for cardiometabolic and other diseases, today announced that it is participating in the BIO Europe 2026 in Cologne.
The conference is an international forum to promote business development between pharmaceutical, financial and biotechnology companies. The event is Europe's largest partnering conference serving the global biotech industry. At this conference leading decision makers of the biotechnology, pharmaceutical and financial industry, employed at emerging companies, meet annually.
The conference is taking place on November 09-11, 2026 in Cologne, with a digital partnering component from November 17-18, 2026.
Recardio is participating and presenting its latest advancements from its drug-based regenerative therapy and is giving a future outlook on new therapies and expansion programs.
About Recardio
Recardio Inc. is a late-stage clinical biotechnology company focused on developing therapies for cardiometabolic and other diseases through a therapeutic platform, designed for disease modification and regeneration.
The company is located in San Francisco, California, with operations in the USA and Europe.
Recardio’s lead drug candidate, dutogliptin, a DPP-IV inhibitor, has demonstrated efficacy in promoting endogenous disease-modifying cardiac regeneration and supporting tissue repair following cardiac injury. The FDA and EMA have approved the global pivotal Phase 3 HEAL-AMI clinical program in acute myocardial infarction for regulatory authorization in major markets.
In addition, the company is advancing multiple cardiometabolic programs in clinical and preclinical development.
For more information, visit: www.recardio.eu or contact pr@recardio.eu
